Tarsus Pharmaceuticals Inc Revenue Growth Rates (TARS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Tarsus Pharmaceuticals Inc   (NASDAQ: TARS)
 

TARS's Revenue Growth by Quarter and Year

Tarsus Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TARS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 173.91
1st Quarter March 162.05
FY 335.96

TARSs Annual Revenue
Tarsus Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 451.36 millions
Tarsus Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 182.95 millions
Tarsus Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 17.45 millions
Tarsus Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 25.82 millions
Tarsus Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 57.03 millions




TARS Revenue second quarter 2026 Y/Y Growth Comment
Tarsus Pharmaceuticals Inc reported Revenue surge of 69.41% year on year in the second quarter 2026, to $ 173.91 millions, this is lower than Tarsus Pharmaceuticals Inc 's recent average Revenue surge of 474.68%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Revenue growth. While Tarsus Pharmaceuticals Inc ' s Revenue jump of 69.41% ranks overall at the positon no. 358 in the second quarter 2026.


TARS Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 128.38 % 407.72 % 30.8 %
3rd Quarter September - 146.67 % 2473.26 % -
2nd Quarter June 69.41 % 151.56 % - -
1st Quarter March 106.85 % 183.74 % 1004.4 % 362.96 %
FY   - 146.72 % 948.42 % -

Financial Statements
Tarsus Pharmaceuticals Inc 's second quarter 2026 Revenue $ 173.91 millions TARS's Income Statement
Tarsus Pharmaceuticals Inc 's second quarter 2025 Revenue $ 102.66 millions Quarterly TARS's Income Statement


TARS Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 27.78 % 38.01 % 599.47 %
3rd Quarter September - 15.62 % 17.91 % -
2nd Quarter June 7.32 % 31.04 % 47.81 % -
1st Quarter March 6.84 % 17.96 % 111.09 % -75 %
FY (Year on Year)   - 146.72 % 948.42 % -


Back to TARS Growth rate Comparisons >> Back to TARS Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #18
Healthcare Sector #94
Overall #358

Revenue Y/Y Growth Statistics
High Average Low
2858.58 % 474.68 % -100 %
(Jun 30 2025)   (Jun 30 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #18
Healthcare Sector #94
Overall #358
Revenue Y/Y Growth Statistics
High Average Low
2858.58 % 474.68 % -100 %
(Jun 30 2025)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Tarsus Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2734.32 % 170.41 % -100 %
(Jun 30 2022)  


TARS's II. Quarter Q/Q Revenue Comment
Tarsus Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue increase of 7.32% quarter on quarter, to $ 173.91 millions.

Within Biotechnology & Pharmaceuticals industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Tarsus Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 970.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #147
Overall #970
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #147
Overall #970
Revenue Q/Q Growth Statistics
High Average Low
2734.32 % 170.41 % -100 %
(Jun 30 2022)  


TARS's II. Quarter Q/Q Revenue Comment
Tarsus Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue increase of 7.32% quarter on quarter, to $ 173.91 millions.

Within Biotechnology & Pharmaceuticals industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Tarsus Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 970.


Tarsus Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 606.33 $ 535.08 $ 451.36 $ 366.10 $ 295.52
Y / Y Revenue Growth (TTM) 105.17 % 128.99 % 146.71 % 182.44 % 254.45 %
Year on Year Revenue Growth Overall Ranking # 70 # 21 # 6 # 23 # 0
Seqeuential Revenue Change (TTM) 13.32 % 18.55 % 23.29 % 23.88 % 26.47 %
Seq. Revenue Growth (TTM) Overall Ranking # 642 # 559 # 47 # 102 # 220


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Tarsus Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 606 millions, company would post below average annual Revenue growth of 26.47% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Tarsus Pharmaceuticals Inc 's Revenue growth from the 162.05% growth in Mar 31 2026.

Within the Healthcare sector 22 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 21 to 70.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 24
Healthcare Sector # 23
Overall # 70

Revenue TTM Y/Y Growth Statistics
High Average Low
254.45 %
 163.55 %
105.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 24
Sector # 136
S&P 500 # 642
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Tarsus Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 606 millions, company would post below average annual Revenue growth of 105.17% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Tarsus Pharmaceuticals Inc 's Revenue growth from the 162.05% growth in Mar 31 2026.

Within the Healthcare sector 22 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 21 to 70.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 24
Healthcare Sector # 23
Overall # 70

Revenue TTM Y/Y Growth Statistics
High Average Low
254.45 %
163.55 %
105.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 24
Sector # 136
S&P 500 # 642




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TARS's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions


About Tarsus Pharmaceuticals Inc Revenue Growth Rates (TARS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Tarsus Pharmaceuticals Inc (CIK 1819790).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001819790-26-000064
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Tarsus Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.